A case report of thrombotic microangiopathy in a patient with advanced pancreatic carcinoma: an emerging, rare, and serious complication
No Thumbnail Available
Date
2025-06
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Medip Academy
Abstract
Thrombotic microangiopathies are characterized by microangiopathic hemolytic anemia and end-organ damage following endothelial injury. The chemotherapeutic agents used in malignancy are one of the important causes of secondary TMA. Both malignancy and TMA are associated with significant morbidity and mortality. Timely recognition of both can result in early target-specific treatment initiation and better outcomes for both diseases. Here, we present a case of TMA in a patient with stage 4 pancreatic carcinoma being treated with Gemcitabine presented with acute kidney disease with new-onset hypertension, edematous illness, and anemia. The patient was Hemodialysis dependent and was treated with steroids, plasma exchange, and rituximab. The patient remained HD dependent 6 months post-treatment and was declared ESRD. Highlighting the importance of early recognition and timely treatment initiation.
Description
Keywords
Thrombotic microangiopathy, Gemcitabine induced-TMA, Acute kidney disease, Plasmapheresis, Chemotherapy-associated complication
Citation
Kandari S, Singh A, Puri R, Cheriyan A, Kaur S. A case report of thrombotic microangiopathy in a patient with advanced pancreatic carcinoma: an emerging, rare, and serious complication. International Journal of Advances in Medicine. 2025 Jun; 12(3): 308-310